<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00046930</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000257122</org_study_id>
    <secondary_id>E3999</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT00046930</nct_id>
    <nct_alias>NCT00046046</nct_alias>
  </id_info>
  <brief_title>Daunorubicin &amp; Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kanisa Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Zosuquidar trihydrochloride, a modulator of multidrug resistance
      (MDR), may help daunorubicin and cytarabine kill more cancer cells by making cancer cells
      more sensitive to the drugs. It is not yet known whether daunorubicin and cytarabine are more
      effective with or without zosuquidar trihydrochloride in treating acute myeloid leukemia or
      anemia.

      PURPOSE: This randomized phase III trial is studying how well giving zosuquidar
      trihydrochloride together with daunorubicin and cytarabine works compared to daunorubicin and
      cytarabine alone in treating older patients with newly diagnosed acute myeloid leukemia or
      anemia that has not responded to previous treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the overall survival and progression-free survival of elderly patients with
           newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts (RAEB) in
           transformation, or high-risk RAEB treated with daunorubicin and cytarabine with or
           without zosuquidar trihydrochloride.

        -  Compare the complete remission rate of patients treated with these regimens.

        -  Compare the toxicity of these regimens in these patients.

        -  Compare the systemic exposure of daunorubicin and cytarabine in patients treated with
           zosuquidar trihydrochloride vs placebo.

      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
      are stratified according to age (60-69 years vs 70 years and over), disease (refractory
      anemia with excess blasts [RAEB] vs RAEB in transformation or acute myeloid leukemia [AML]),
      and disease type (de novo vs secondary). Patients are randomized to 1 of 2 treatment arms.

        -  Induction:

             -  Arm I: Patients receive daunorubicin via intravenous (IV) infusion over 10-15
                minutes and zosuquidar trihydrochloride IV over 6 hours on days 1-3. Patients also
                receive cytarabine IV continuously on days 1-7.

             -  Arm II: Patients receive daunorubicin and cytarabine as in arm I. Patients also
                receive placebo IV over 6 hours on days 1-3.

      Beginning on day 12, patients who achieve aplasia receive filgrastim (G-CSF) or sargramostim
      (GM-CSF) subcutaneously (SC) or IV daily until blood counts recover. Patients who have
      evidence of persistent AML are eligible to receive a second identical course of induction
      chemotherapy.

        -  Consolidation I (beginning within 8 weeks after documentation of complete remission [CR]
           or measurable remission [MR]): Patients who achieve a CR or MR receive cytarabine IV
           over 1 hour once or twice daily on days 1-6 and GM-CSF or G-CSF SC or IV beginning on
           day 7 and continuing until blood counts recover.

        -  Consolidation II: Patients who have maintained peripheral blood evidence of a remission
           receive daunorubicin, cytarabine, and zosuquidar trihydrochloride or placebo as in
           induction chemotherapy. Patients also receive GM-CSF or G-CSF SC or IV beginning on day
           8 or after last cytarabine dose and continuing until blood counts recover.

      Patients are followed monthly for 1 year, every 2 months for 1 year, every 3 months for 1
      year, and then every 6 months for 2 years.

      PROJECTED ACCRUAL: Approximately 450 patients (225 per treatment arm) accrued over 4.1 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually thereafter</time_frame>
    <description>Time from randomization to death. Patients alive at last follow-up were censored.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually thereafter</time_frame>
    <description>Time from randomization to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>Assessed at the end of induction</time_frame>
    <description>Number of eligible participants in each response category. Categories, based on peripheral blood counts and bone marrow aspirate and biopsy, include complete remission (CR), partial remission (PR), morphologic complete remission (MCR), and relapse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Zosuquidar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment with daunorubicin, cytarabine and zosuquidar (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction treatment with daunorubicin, cytarabine and placebo (details provided in Intervention section), followed by consolidation with Cytarabine (1500 mg/m2 every 12 hours for 6 days), then additional consolidation with the same regimen as received during induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to &gt; 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.</description>
    <arm_group_label>Zosuquidar</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Neupogen, recombinant-methionyl human granulocyte-colony stimulating factor,</other_name>
    <other_name>granulocyte colony-stimulating factor, r-metHuG-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to &gt; 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.</description>
    <arm_group_label>Zosuquidar</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Granulocyte-macrophage colony stimulating factor, rHu GM-CSF,</other_name>
    <other_name>Leukine, NSC # 617589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).</description>
    <arm_group_label>Zosuquidar</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cytosar-U, Ara-C, Arabinosyl, cytosine arabinoside.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daunorubicin hydrochloride</intervention_name>
    <description>45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).</description>
    <arm_group_label>Zosuquidar</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Daunomycin, Rubidomycin, Cerubidine.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zosuquidar trihydrochloride</intervention_name>
    <description>Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.
The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3.</description>
    <arm_group_label>Zosuquidar</arm_group_label>
    <other_name>Multi drug resistance modulator, MDR, LY335979</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.
The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Baxter Infuvite Adult</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        One of the following disorders:

          -  Acute myeloid leukemia (AML), defined as &gt;30% myeloblasts on the marrow aspirate or
             peripheral blood differential and any French-American-British (FAB) subtype except M3
             (i.e., acute promyelocytic leukemia)

          -  Refractory anemia with excess blasts (RAEB), defined as 11-20% myeloblasts on bone
             marrow aspirate or peripheral blood differential, provided there are other criteria
             for high-risk disease

          -  Refractory anemia with excess blasts in transformation (RAEB-T), defined as 21-30%
             myeloblasts on bone marrow aspirate or peripheral blood differential

          -  Participants may have secondary AML

          -  Age greater than 60 years

          -  ECOG performance status of 0 to 3

          -  Total serum bilirubin &lt; 3 mg/dL

          -  Serum creatinine &lt; 2 mg/dL

          -  Cardiac ejection fraction of &gt; 45%

        Exclusion Criteria:

          -  Blastic transformation of chronic myelogenous leukemia

          -  CNS leukemia

          -  Prior chemotherapy for AML, with the exception of hydroxyurea

          -  For women: pregnant or breast feeding

          -  Other malignancy for which participant is currently receiving treatment

          -  Concurrent treatment with other colony-stimulating factors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry D. Cripe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University Melvin and Bren Simon Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCOP - Mayo Clinic Scottsdale Oncology Program</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Presbyterian Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulder Community Hospital</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Cancer Center at Penrose Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80933</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porter Adventist Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian - St. Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Colorado Cancer Research Program, Incorporated</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80224-2522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sky Ridge Medical Center</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Cancer Care Center at Longmont United Hospital</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary-Corwin Regional Medical Center</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Suburban Medical Center</name>
      <address>
        <city>Thorton</city>
        <state>Colorado</state>
        <zip>80229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Clinic, LLC</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute at University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP-Medical College of Georgia Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Associates</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital Cancer Care Institute</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Health Care - Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center at Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center at Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center at Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic, P.C.</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siouxland Hematology-Oncology Associates</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Regional Medical Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Chanute</name>
      <address>
        <city>Chanute</city>
        <state>Kansas</state>
        <zip>66720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Dodge City</name>
      <address>
        <city>Dodge City</city>
        <state>Kansas</state>
        <zip>67801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Kingman</name>
      <address>
        <city>Kingman</city>
        <state>Kansas</state>
        <zip>67068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Medical Center</name>
      <address>
        <city>Liberal</city>
        <state>Kansas</state>
        <zip>67901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Newton</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pratt Cancer Center of Kansas</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Salina</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Wellington</name>
      <address>
        <city>Wellington</city>
        <state>Kansas</state>
        <zip>67152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Womens Health</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, P.A.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, P.A. - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Cancer Center at Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Winfield</name>
      <address>
        <city>Winfield</city>
        <state>Kansas</state>
        <zip>67156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts - New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Regional Cancer Program at D'Amour Center for Cancer Care</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Cancer Center at St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazooaa</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute at Abbott-Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubert H. Humphrey Cancer Center at North Memorial Medical Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clinic</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ridgeview Medical Center</name>
      <address>
        <city>Waconia</city>
        <state>Minnesota</state>
        <zip>55387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center of Southern Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Southern Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern New Jersey</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Booker Cancer Center at Riverview Medical Center</name>
      <address>
        <city>Red Bank</city>
        <state>New Jersey</state>
        <zip>07701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leo W. Jenkins Cancer Center at Pitt County Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital Cancer Center at Aultman Health Foundation</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth's Cancer Care Center at MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital Cancer Center</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-2001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Medical Center - Sayre</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Associates</name>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Group</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sioux Valley Hospital and University of South Dakota Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Babb Randolph Cancer Center at West Virginia University Hospitals</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>South Africa</country>
  </removed_countries>
  <results_reference>
    <citation>Cripe LD, Li X, Litzow M, et al.: A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for Pts &gt; 60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999. [Abstract] Blood 108 (11): A-423, 2006.</citation>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>August 17, 2010</results_first_submitted>
  <results_first_submitted_qc>August 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 6, 2010</results_first_posted>
  <last_update_submitted>June 1, 2015</last_update_submitted>
  <last_update_submitted_qc>June 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zosuquidar</title>
          <description>Induction treatment with daunorubicin, cytarabine and zosuquidar</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Induction treatment with daunorubicin, cytarabine and placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="221"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zosuquidar</title>
          <description>Induction treatment with daunorubicin, cytarabine and zosuquidar</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Induction treatment with daunorubicin, cytarabine and placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
            <count group_id="B2" value="221"/>
            <count group_id="B3" value="433"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.4" spread="5.5"/>
                    <measurement group_id="B2" value="69.2" spread="5.3"/>
                    <measurement group_id="B3" value="69.3" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Time from randomization to death. Patients alive at last follow-up were censored.</description>
        <time_frame>Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually thereafter</time_frame>
        <population>Eligible participants, as randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Zosuquidar</title>
            <description>Induction treatment with daunorubicin, cytarabine and zosuquidar</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Induction treatment with daunorubicin, cytarabine and placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Time from randomization to death. Patients alive at last follow-up were censored.</description>
          <population>Eligible participants, as randomized</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" lower_limit="5.62" upper_limit="10.58"/>
                    <measurement group_id="O2" value="9.43" lower_limit="8.02" upper_limit="10.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was designed to have 80% power to detect a non-proportional hazards difference in OS at the one-sided 0.025 significance level of 30.2% vs 39.6%, 12.8% vs 27.1% and 7.0% vs 14.0% at 1 years, 2 years, and full information for zosuquidar and placebo, respectively.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified on age (&lt; 70 vs. &gt;=70) and type of leukemia (de novo AML, secondary RAEB-t, or secondary RAEB AML)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Time from randomization to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored.</description>
        <time_frame>Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually thereafter</time_frame>
        <population>Eligible participants, as randomized. Patients who had neither documented progression nor death within 3 months of registration without disease evaluation were excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Zosuquidar</title>
            <description>Induction treatment with daunorubicin, cytarabine and zosuquidar</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Induction treatment with daunorubicin, cytarabine and placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Time from randomization to the earlier of disease progression or death. Patients alive and progression-free at last follow-up were censored.</description>
          <population>Eligible participants, as randomized. Patients who had neither documented progression nor death within 3 months of registration without disease evaluation were excluded.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="2.04" upper_limit="3.84"/>
                    <measurement group_id="O2" value="2.04" lower_limit="1.64" upper_limit="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Log Rank</method>
            <method_desc>Stratified on age and type of leukemia</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response</title>
        <description>Number of eligible participants in each response category. Categories, based on peripheral blood counts and bone marrow aspirate and biopsy, include complete remission (CR), partial remission (PR), morphologic complete remission (MCR), and relapse.</description>
        <time_frame>Assessed at the end of induction</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zosuquidar</title>
            <description>Induction treatment with daunorubicin, cytarabine and zosuquidar</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Induction treatment with daunorubicin, cytarabine and placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Response</title>
          <description>Number of eligible participants in each response category. Categories, based on peripheral blood counts and bone marrow aspirate and biopsy, include complete remission (CR), partial remission (PR), morphologic complete remission (MCR), and relapse.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morphologic Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unevaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of difference in the CR (complete remission) rate between the arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.617</p_value>
            <p_value_desc>Test was stratified on age and type of leukemia.</p_value_desc>
            <method>Mantel Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.65</ci_upper_limit>
            <estimate_desc>Zosuquidar/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed every day until discharged from hospital, then twice weekly until ANC and platelets returned to normal levels. Complete blood counts were obtained monthly for 12 months, then every other month for 12 months.</time_frame>
      <desc>In addition to lab assessed as above, clinical events were reported via case report forms at the end of Induction, Consolidation I, and Consolidation II. After the end of treatment, forms were collected every 3 months for 2 years, then every 6 months for 3 years. CTCv2 reports were electronically mapped to CTCAE3.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zosuquidar Induction</title>
          <description>Induction treatment with daunorubicin, cytarabine and zosuquidar</description>
        </group>
        <group group_id="E2">
          <title>Placebo Induction</title>
          <description>Induction treatment with daunorubicin, cytarabine and placebo</description>
        </group>
        <group group_id="E3">
          <title>Consolidation I</title>
          <description>Cytarabine 1500 mg/m2 days 1-6</description>
        </group>
        <group group_id="E4">
          <title>Zosuquidar Consolidation II</title>
          <description>Consolidation with Daunorubicin, Cytarabine and Zosuquidar</description>
        </group>
        <group group_id="E5">
          <title>Placebo Consolidation II</title>
          <description>Consolidation with Daunorubicin, Cytarabine and Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="218" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="173" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Marrow Hypocellularity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="211" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="200" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="202" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="153" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="169" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Transfusion: Platelets</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Transfusion: Peripheral Red Blood Cells</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hematologic - Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Thrombotic Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU, Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hemorrhage, Upper Respiratory, Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hemorrhage Associated with Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Melena</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI, Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GU, Vagina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lymphatics, Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Conduction Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dysrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Supraventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Arrhythmia - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac - Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac Troponin I Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac Troponin T Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Acute Vascular Leak Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac, Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Neuroendocrine: ADH Secretion Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vision - Blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Ulcer, Gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o Prior Colostomy</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhea w/Colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>GI, Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Rectum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Constitutional, Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Dysfunction/Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hepatic, Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Catheter Related</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Infection w/ Grade 3 or 4 Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Infection w/ Unknown ANC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Infection without Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Infection, Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Other</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fibrinogen Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Prolonged Partial Thromboplastin Time</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>PT (INR) Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyl Transpeptidase (GGT) Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>ALT, SGPT Increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>AST, SGOT Increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Amylase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Bicarbonate, Serum Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Tumor Lysis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Joint (Arthralgia)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Muscle (Myalgia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Psychosis (Hallucinations/Delusions)</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Somnolence/Depressed Level of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Mood Alteration: Anxiety/Agitation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Mood Alteration: Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Neuropathy, Motor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Neuropathy, Sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pyramidal Tract Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Neurologic - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal, Other - Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Incontinence, Urinary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Urinary Frequency/Urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Renal, Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, Upper Respiratory, Nose</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pneumonitis/Pulmonary Infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Voice changes/Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pulmonary, Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis/itching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Wound, Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="221" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="180" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="215" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="179" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="152" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="69" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="67" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Heartburn/Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Taste Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o Prior Colostomy</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Abdomen</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rigors/Chills</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>AST, SGOT Increased</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>ALT, SGPT Increased</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Joint (Arthralgia)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Bone</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Muscle (Myalgia)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain, Headache</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pruritis/Itching</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rash/Desquamation</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="222"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="180"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>ECOG Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

